Kidney procedures and drugs:


FDA APPROVES RX HERCULINK FOR
KIDNEY STENTING IN THE US
In August 2011
 Abbott  received a U.
S. Food and Drug Administration
(FDA) approval for the RX Herculink
Elite  Renal Stent System for the
treatment of renal artery stenosis
(narrowing of the main arteries
supplying blood to the kidneys) in
patients with uncontrolled hypertension
(high blood pressure).

Over time, narrowed kidney arteries
can lead to kidney failure and
increased risk of heart disease, stroke
and peripheral artery disease.

This approval is supported by the
HERCULES (Herculink Elite Cobalt
Chromium Renal Stent Trial to
Demonstrate Efficacy and Safety)
study, which demonstrated that RX
Herculink Elite is safe and effective in
patients with renal artery stenosis and
uncontrolled hypertension.

"One striking result of the HERCULES
study was the reduction in blood
pressure we saw with RX Herculink
Elite in patients with uncontrolled
hypertension – those who are not
adequately managed with multiple
blood pressure medications," said
Michael R. Jaff, D.O., medical director  
at the Massachusetts General Hospital
in Boston. "This result supports renal
stenting as an important treatment
option, as elevations in blood pressure
can increase heart disease and stroke
risk in patients with renal artery
stenosis."

RX Herculink Elite has been
commercially available in Europe since
2007 for peripheral indications.




SILVER ALLOY URINARY
CATHETERS REDUCE URINARY
TRACT INFECTIONS
Silver alloy urinary catheters reduce
catheter-associated urinary tract
infections compared with standard
silicone or latex urinary catheters in  
hospitalised adult patients.

Patients with urinary catheters are at
an increased risk of infection. These
catheters are inserted into the bladder
via the urethra , or through the
abdominal wall, so essentially the body
treats them as a foreign element.

The body's natural ability to cleanse
the urinary tract of microorganisms is
reduced because the passage of urine
does not flush the urinary tract when a
urinary catheter is in place.

Microorganisms can be transmitted by
poor handwashing by healthcare
workers, breakages in the closed
urinary collection systems and by
movement from one part of the body to
another, such as the transmission of
bacteria from bowel to urethral
opening.

Bacteria can be free-floating or can
colonise into biofilms that attach
themselves to the catheter surface and
may cause catheter blockage.  
Reducing biofilm formation is therefore
important in reducing UTI.

One of the strategies believed to
reduce UTI is the use of silver alloy
urinary catheters. Silver has been
used in healthcare for centuries and is
known for its wide spectrum
antimicrobial properties.

The Centre for Evidence-Based
Purchasing in the UK has suggested
the silver coating within urinary
catheters reduces biofilm formation, as
well as colonization by releasing silver
ions into the urinary tract. Despite this,
the use of silver alloy urinary catheters
are slow to catch up, because it costs
substantially more than the current
type.

But several studies have found that
silver alloy urinary catheters do offer
significant savings when the extra cost
of hospitalization is figured in.




NEW MEMOKATH STENT FOR
KIDNEY STENTING
The new Memokath stents are made
from metal rather than plastic and last
for ten years rather than six months.
They're also more comfortable and
reduce the risk of urine infections.
Memokath - a safe, simple and reliable
Nickel-Titanium stent with thermal
shape-memory effect for treating
Urinary Tract Obstruction made by
PNN Medical.
The Memokath  stents are used for
treating men with prostatic obstruction
and enlargement, for urethral
strictures or ureteric obstructions in
both men and women.



NEW  DRUG  FOR CHRONIC KIDNEY
DISEASE IMPROVES KIDNEY
FUNCTION
In two Phase 2 clinical trials, the new
drug bardoxolone significantly
improved kidney function in patients
with advanced chronic kidney disease
and Type 2 diabetes.
Bardoxolone is an oral, first-in-class
antioxidant inflammation modulator that
works by increasing the estimated
glomerular filtration rate (eGFR) of the
kidneys.
The glomerular filtration rate is the rate
at which blood is filtered through all of
the glomeruli, and thus the measure of
the overall renal function.  
A glomerulus is the basic filtration unit
of the kidney.

Abbott and Reata Pharmaceuticals will
collaborate  to develop and
commercialize bardoxolone.

Chronic kidney disease is a highly
prevalent condition, affecting more
than 50 million adults around the
world.  Half of the patients also have
diabetes.
Diabetes is the leading cause of
chronic kidney disease, with as many
as 30 to 40 percent of Type 2
diabetics developing the disease.  
Available therapies modestly slow the
progression, and patients ultimately
progress to dialysis.